New combo before lung cancer surgery shows promise in early trial
NCT ID NCT07264647
First seen Dec 16, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tests whether giving a combination of immunotherapy (tislelizumab) and chemotherapy before surgery can help more people with stage III PD-L1 positive non-small cell lung cancer have a complete removal of their tumor. About 30 adults who are current or former smokers and have not had prior treatment will participate. The main goal is to see how many patients can undergo successful radical surgery after this pre-surgery treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Fisioterapici Ospitalieri
RECRUITINGRome, Roma (RM), 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.